The James P. Allison Institute at MD Anderson Cancer Center established an 11-person scientific advisory board to provide strategic guidance and evaluation of its research portfolio and programs.
Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.
